Medication Competition Act requires the Secretary of Health and Human Services to determine exclusivity periods for licensed biological products.
The Medication Competition Act amends the Public Health Service Act to mandate the Secretary of Health and Human Services to establish the exclusivity periods for licensed biological products. This includes determining the expiration dates for exclusivity periods for products licensed before and after the act's enactment. The Secretary must publish these determinations within specified timeframes, ensuring transparency and timely information for stakeholders.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
Analyze for Free
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.